Eporgen Venture is the first Italian company, entirely funded by private, non-institutional investors, which is dedicated to seed capital investments in the area of life sciences.

Eporgen’s mission is to identify and select innovative projects in the area of life sciences, in which it invests in order to create a balanced portfolio of small start-up companies that are supported in their management and controlled by Eporgen. These start-up companies are built around intellectual property that is being developed up to a proof-of-concept stage and subsequently licensed out to suitable partners, to generate new economic resources.

The current portfolio of Eporgen is constituted of eleven start-up companies, with innovative early stage therapeutics and diagnostics that cover diverse disease areas (oncology, anti-infectives, cardiovascular), approaches (small molecules, proteins, peptides, vaccines) and technology applications.